Breaks Categories: Stock Spotlights

WednesdayMay 26, 2021 1:01 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Cancer Visualization Technology Holds Significant Potential

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022,” reads a recent article on the innovative solution. “Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing…

Continue Reading

MondayMay 24, 2021 1:31 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Tailoring Solutions to Customers’ Needs, Budget

United Medical Equipment (“UME,” “UMEBSNI”) is playing a vital role in making it possible for businesses and health care facilities to maintain safety and health among employees and customers by supplying personal protective equipment (“PPE”) and rapid antibody test kits. UME’s contribution is essential now more than ever due to factors such as the uncertainty surrounding the ability of the vaccines to suppress the spread of COVID-19 completely, given the limited observation period, as well as the fact that those vaccinated can spread the virus. “By offering COVID-19 rapid kit testing, the company is doing its part and continually evolving…

Continue Reading

FridayMay 21, 2021 3:00 pm

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) Specialized Team Poised to Expand Doctor-to-Doctor, Consumer Sales

Healthy Extracts (OTCQB: HYEX) recently announced the addition of Dr. Joel Kahn, MD, to its medical board. Dr. Kahn, a world-renowned, triple board-certified cardiology specialist with 30 years of experience, has used BergametNA Citrus Bergamot SuperFruit(TM) on thousands of patients and approves the product’s cardiovascular health benefits. He has also personally conducted clinical studies that confirm the effectiveness of the superfruit, the main ingredient in BergametNA’s product line. HYEX CEO Duke Pitts noted that the company was delighted to welcome Dr. Kahn to its medical board. A recent article discussing this indicates that Pitts considers the addition of Dr. Kahn…

Continue Reading

ThursdayMay 20, 2021 12:16 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s three strategic initiatives. “Develop” is its first initiative, under which Tryp intends to utilize FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.…

Continue Reading

WednesdayMay 19, 2021 2:45 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Is Pushing Boundaries of What Is Possible in Neurology Research

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was recently featured in Neoscope (a publication by Futurism) as a company that champions cutting-edge research that is shaping the future in the field of brain diagnostics. “The article details Brain Scientific’s e-tattoo technology — a series of tiny electrodes stitched beneath the skin that can get a clear reading of neural signals in real-time,” reads a recent update regarding the company and its ground-breaking technology. “The feature reports that Brain Scientific is exploring possibilities to use big data collected through e-tattoo to study the neurological…

Continue Reading

TuesdayMay 18, 2021 3:13 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and…

Continue Reading

TuesdayMay 18, 2021 2:59 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes ‘Exceptional’ Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, was featured in a recent article that discussed its timely progress toward 2022 completion of its innovative i/Blue Imaging System(TM). The patented system is designed leveraging proprietary light sensors and optics to improve the efficiency and accuracy of bladder cancer visualization and removal. According to the update, the on-track progress can be largely attributed to the company’s selection of Lighthouse Imaging as its manufacturing partner. “Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal…

Continue Reading

FridayMay 14, 2021 1:35 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

Continue Reading

FridayMay 14, 2021 12:38 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments…

Continue Reading

WednesdayMay 12, 2021 12:48 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Poised for Opportunity in Burgeoning Global Health Products Sector

Healthy Extracts (OTCQB: HYEX) is well-positioned to capitalize further on the rapidly growing health products market, which has already positively impacted the company. “The increasing interest, which has led to more demand for the products, has positively impacted HYEX, as evidenced by the company’s improved revenue from $748,377 in 2019 to $1,276,559 in 2020, representing a 71% jump,” reports a recent article. Healthy Extracts wholly owns two subsidiaries — Ultimate Brain Nutrients (“UBN”) and BergaMet North America. The global brain health supplements market, UBN’s domain, “is projected to reach $13.38 billion by 2028, marking a CAGR of 8.0% from 2021…

Continue Reading